In current position since 2017.
Education: Ph.D. in Biochemistry in 1999 and M.Sc. in Chemistry in 1993 from the Faculty of Engineering (LTH), Lund University.
Experience and prior assignments: Sarah Fredriksson founded Genovis AB and during her time as CEO for more than 15 years, Genovis’ product concept was developed and launched and the company was listed on First North, Nasdaq OMX Nordic. She has many years of experience from research and development in biotech from both academia and industry. For several years now, she has been active as an entrepreneur, CEO and board member in unlisted and listed life science companies such as Genovis AB (publ), Edvince AB, Geccodots AB, Respiratorius AB (publ) as well as the board of Lund University and the national non-profit association for the life science industry SwedenBIO AB.
Other current assignments: Board member of LU Holding, Faculty of Engineering (LTH).
Holdings: 30,520 shares.
In current position since 2018.
Education: Ph.D. in Chemistry, 1994 and B.Sc. in Chemistry 1989, Umeå University.
Experience and prior assignments: Fredrik Lindgren’s background is in the pharmaceutical industry, with experience from key positions in areas such as business development processes at AstraZeneca and LEO Pharma. among others. Most recently he held the position of Senior Director, Head of Global Business Development, at LEO Pharma.
Other current assignments: None
Holdings: 24,000 shares.
In current position since 2021.
Education: M.D., Ph.D. 1986 Karolinska Institutet; Post-doctoral studies 1987-1989 UT Southwestern Medical Center, Texas; Associate Professor 1990 Karolinska Institutet; Professor 1996 University of Bergen.
Experience and prior assignments: Dr. Johan Lund has many years of experience from executive positions in pharmaceutical research and development. He is the CEO and founder of KyNexis Medicine Development AB and the founder of MBS Pharma AB. Most recently, he was Vice President of Translational R&D at Celgene, in Cambridge, Massachusetts, USA, with responsibility for early research and development in inflammation and immunology. Previous positions include Chief Scientific Officer, Immunoscience Research Unit at Pfizer, Cambridge, Massachusetts, as well as 14 years at AstraZeneca in executive positions in Sweden and the UK as Vice President CNS & Pain Innovative Medicines Science and Vice President Respiratory and Inflammation Research. Previously Chairman of the Board at AQILION AB.
Other current assignments: Board member of Olink Proteomics AB, Genagon Therapeutics AB, NEOGAP AB, Pelago AB, KyNexis Medicine Development AB, MBS Pharma AB and LIDDS AB.
Holdings: 38,160 through company.
In current position since 2020.
Education: Degree in business administration from the Norwegian School of Economics (NHH) and a Ph.D. in Business Administration from the University of California, Berkeley, USA.
Experience and prior assignments: Torgeir Vaage has more than 20 years of combined experience in the life science industry and the financial sector. In recent years, he has worked in Denmark and Norway as CFO and CEO for several small biotech companies with a focus on pharmaceuticals. Prior to that he was a senior analyst and partner at ABG Sundal Collier, senior capital analyst at Handelsbanken and management consultant at AT Kearney in Oslo.
Other current assignments: CFO of Initiator Pharma and Acesion Pharma.
Holdings: 26,500 shares through company.